ConductScience.org, home
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
API referenceFor AI assistants

Trial · NCT03416179

Adverse events1,336

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 1,336

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
otherAnaemiaBlood and lymphatic system disordersIntensive Study: Glasdegib + Cytarabine + Daunorubicin101198
otherAnaemiaBlood and lymphatic system disordersIntensive Study: Placebo + Cytarabine + Daunorubicin97201
otherAnaemiaBlood and lymphatic system disordersNon-intensive Study: Glasdegib + Azacitidine73162
otherAnaemiaBlood and lymphatic system disordersNon-intensive Study: Placebo + Azacitidine71160
otherFebrile neutropeniaBlood and lymphatic system disordersIntensive Study: Glasdegib + Cytarabine + Daunorubicin97198
otherFebrile neutropeniaBlood and lymphatic system disordersIntensive Study: Placebo + Cytarabine + Daunorubicin96201
otherFebrile neutropeniaBlood and lymphatic system disordersNon-intensive Study: Glasdegib + Azacitidine23162
otherFebrile neutropeniaBlood and lymphatic system disordersNon-intensive Study: Placebo + Azacitidine22160
otherLeukopeniaBlood and lymphatic system disordersIntensive Study: Glasdegib + Cytarabine + Daunorubicin10198
otherLeukopeniaBlood and lymphatic system disordersIntensive Study: Placebo + Cytarabine + Daunorubicin13201
otherLeukopeniaBlood and lymphatic system disordersNon-intensive Study: Glasdegib + Azacitidine13162
otherLeukopeniaBlood and lymphatic system disordersNon-intensive Study: Placebo + Azacitidine4160
otherNeutropeniaBlood and lymphatic system disordersIntensive Study: Glasdegib + Cytarabine + Daunorubicin41198
otherNeutropeniaBlood and lymphatic system disordersIntensive Study: Placebo + Cytarabine + Daunorubicin43201
otherNeutropeniaBlood and lymphatic system disordersNon-intensive Study: Glasdegib + Azacitidine38162
otherNeutropeniaBlood and lymphatic system disordersNon-intensive Study: Placebo + Azacitidine30160
otherThrombocytopeniaBlood and lymphatic system disordersIntensive Study: Glasdegib + Cytarabine + Daunorubicin52198
otherThrombocytopeniaBlood and lymphatic system disordersIntensive Study: Placebo + Cytarabine + Daunorubicin52201
otherThrombocytopeniaBlood and lymphatic system disordersNon-intensive Study: Glasdegib + Azacitidine38162
otherThrombocytopeniaBlood and lymphatic system disordersNon-intensive Study: Placebo + Azacitidine35160

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03416179/events

API referenceFor AI assistants